TY - JOUR
T1 - Spotlight on nivolumab in the treatment of renal cell carcinoma
T2 - Design, development, and place in therapy
AU - Venur, Vyshak Alva
AU - Joshi, Monika
AU - Nepple, Kenneth G.
AU - Zakharia, Yousef
N1 - Publisher Copyright:
© 2017 Venur et al.
PY - 2017/4/11
Y1 - 2017/4/11
N2 - Several tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptors and molecules inhibiting the mammalian target of rapamycin are being used for management of metastatic renal cell carcinoma (mRCC); however, there is still a potential for improvement. Immune checkpoint inhibitors like nivolumab and other PD-1/PD-L1 inhibitors provide an alternative approach for patients with mRCC. In this article, the authors review the safety profile and outcomes of phase 1, 2, and 3 clinical trials of nivolumab in mRCC.
AB - Several tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptors and molecules inhibiting the mammalian target of rapamycin are being used for management of metastatic renal cell carcinoma (mRCC); however, there is still a potential for improvement. Immune checkpoint inhibitors like nivolumab and other PD-1/PD-L1 inhibitors provide an alternative approach for patients with mRCC. In this article, the authors review the safety profile and outcomes of phase 1, 2, and 3 clinical trials of nivolumab in mRCC.
UR - http://www.scopus.com/inward/record.url?scp=85018470374&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018470374&partnerID=8YFLogxK
U2 - 10.2147/DDDT.S110209
DO - 10.2147/DDDT.S110209
M3 - Review article
C2 - 28442891
AN - SCOPUS:85018470374
SN - 1177-8881
VL - 11
SP - 1175
EP - 1182
JO - Drug Design, Development and Therapy
JF - Drug Design, Development and Therapy
ER -